Fastest
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →https://www.patsnap.com/resources/blog/rd-blog/perfusion-and-process-intensification-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Single-Use BioprocessingPerfusion and Process Intensification Patents: Who Leads and Where Filing Is Heading
- 35.7% of all 4,506 records sit with just five assignees, so most of the claim space around cell retention and perfusion control is already staked out by a small group.
- Filing peaked in 2021 at 322 and fell 33% to 215 by 2024, the last year the dataset treats as complete — a real pullback, not a data artefact.
- Bioreactor apparatus claims (C12M) sit under a quarter of records at 25.1%, well behind the C12N and C07K classes that dominate the field, pointing to lighter coverage on hardware than on the biology itself.
4,506
Published Records
36%
Top-5 Share of All Records
-33%
Filing Growth 2021→2024
US
Leading Jurisdiction
Filing growth compares 2021 (322 records) with 2024 (215) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 4,506 records in scope (CR5), not by the ranked leaders only.
Published byPatsnap Research··7 min readSourced from Patsnap Eureka
Overview
What this landscape covers
This dataset tracks patent families filed against perfusion culture, cell retention devices and process intensification language, cross-referenced against operational terms like viable cell density, filter fouling and steady-state operation. It spans 4,506 published records filed between 2015 and the mid-2026 data cut-off, drawing on assignee, IPC and citation data across major receiving offices including the United States, the EPO, WIPO and Australia.
The scope favours upstream process claims over downstream purification, and captures both device-level filings (retention filters, ATF systems) and method-level filings (perfusion rate control, seed train shortening). Readers should treat the most recent one to two years of filings as understated, since publication typically lags filing by roughly 18 months.
Filing volume and technology composition, 2015-2026
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Perfusion and Process Intensification covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
The Numbers
Filing trends and technology composition
Two views of the same 4,506-record set: how filing volume has moved year over year, and which technical branches carry the claim density.
A decade of filing, with a clear post-2021 pullback
Annual filings rose from 205 in 2017 to a peak of 322 in 2021, then declined to 215 by 2024 — a 33% drop over that three-year span. Volumes in 2025 and 2026 appear lower still, but that reflects publication lag rather than a real collapse in activity; those years are not yet complete in the record.
Biology-heavy composition, apparatus claims thinner
C12N (microorganisms and genetic engineering) appears in 57.6% of records and C07K (peptides and proteins) in 37.6%, reflecting how much of this corpus is anchored in what is being cultured rather than how. C12M (bioreactors and enzyme apparatus), the class closest to physical retention hardware, covers 25.1% of records — a meaningful but secondary share, and one that leaves room for apparatus-specific claims that do not overlap the dominant biological classes.
Shares are the percentage of the 4,506 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Perfusion and Process Intensification covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.
Go deeper on Perfusion and Process Intensification with Eureka
This page is one run against one query. Ask Eureka your own question about perfusion and process intensification and every answer comes back with the patent numbers behind it.
Try EurekaKey Patents
The documents anchoring this field
Representative Filing
SG11201809051YA — Cell retention device and method
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Filed by Boehringer Ingelheim International GmbH, this filing sits squarely in the cell retention device sub-area and represents the kind of apparatus-plus-method claim that recurs across the perfusion segment of this dataset.Filing date and current legal status are rendered separately from live data.
View full filing recordMost-cited records in scope
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US6566118B1 | Methods for generating high titer helper-free preparations of released recombinant AAV vectors | 954 |
| 2 | US6989264B2 | Methods for generating high titer helper-free preparations of released recombinant AAV vectors | 452 |
| 3 | US6995006B2 | Methods for generating high titer helper-free preparations of released recombinant AAV vectors | 396 |
| 4 | WO1999011764A2 | Methods for generating high titer helper-free preparations of recombinant AAV vectors | 385 |
| 5 | US5672502A | Animal cell culture | 261 |
| 6 | EP1229125A1 | Process for producing polypeptide | 237 |
| 7 | US20040077075A1 | Microfermentors for rapid screening and analysis of biochemical processes | 168 |
| 8 | US20160145563A1 | Distributed perfusion bioreactor system for continuous culture of biological cells | 158 |
| 9 | WO2013006479A2 | Mammalian cell culture | 156 |
| 10 | WO2005095578A1 | Process for cell culturing by continuous perfusion and alternating tangential flow | 152 |
Citation counts reward older filings that have had more time to accumulate references — read them as a signal of influence on subsequent filings, not as a ranking of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Perfusion and Process Intensification covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself
Put your own technology through the same analysis
Where to run it
For builders
MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Insights
What the data means for filing strategy
Three patterns worth acting on before drafting new claims in this space.
Concentration
35.7%
of 4,506 records held by top 5
The top of the field is settled, not open
Five assignees hold 35.7% of all 4,506 records in scope, and the top ten extend that to 47.4%. New entrants drafting broad perfusion-method claims should expect to run into this cluster's prior art almost immediately, particularly around cell retention and viable cell density control.
Concentration figures from assignee ranking
Momentum
-33%
filings 2021 to 2024
Peak filing has passed, at least for now
Filings peaked at 322 in 2021 and had fallen to 215 by 2024, a 33% decline over three years. Several of the largest historical filers show steep year-on-year drops in the most recent complete year, suggesting the earlier land-grab phase for core perfusion claims is winding down even as the field's activity has not stopped.
2021-2024 filing trend
Class balance
10.3%
of records touch B01D separation processes
Filtration and separation claims are a minority lane
B01D (separation processes, including filtration) appears in only 10.3% of records, and G01N (material analysis and testing) in just 3.4%. Given how central filter fouling and cell retention devices are to the search terms defining this dataset, that relatively light coverage marks these as areas where claim space is less crowded than the biology-heavy classes.
IPC subclass shares, of 4,506 records
Eureka AI Agent
Looking for what nobody has claimed yet?
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to perfusion and process intensification, with the prior art for and against each one.
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Perfusion and Process Intensification covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Players
Who is filing, and who has slowed down
The 100-company ranking behind this dataset shows a familiar biologics-manufacturing cluster at the top, but recent-year momentum tells a more mixed story than the cumulative totals suggest.
Leader
772
records, the largest single assignee
One filer sits well ahead of the field
The leading assignee holds 772 records, more than four times the fifth-place holder's 174. That gap is unusually wide even for a concentrated field, and it means freedom-to-operate checks in this space should start with that single portfolio before moving to the broader top ten.
Assignee ranking, 100 companies
Momentum
-77% to -100%
YoY change among several major historical filers
Several top filers have gone quiet
Multiple assignees that built large cumulative portfolios show sharp year-on-year declines in the latest year, including drops of -77%, -88% and full stops at -100% among some of the largest historical filers. This does not necessarily mean disengagement — some of that gap is publication lag — but it is a real shift in visible filing activity worth tracking assignee by assignee.
Recent-year momentum by assignee
Collaboration
10
co-assignee pairs identified
Co-filing is limited and concentrated
Only 10 co-assignee pairs appear in this dataset, and the strongest of them links two of the field's largest filers at 48 shared records. Co-filing here looks like an artefact of corporate structure and long-standing R&D partnerships rather than a broad pattern of cross-company collaboration.
Co-assignee pair analysis
Recent-year filing momentum by assignee
| Assignee | Recent year | YoY |
|---|---|---|
| Amgen Inc. | 12 | -77% |
| Genentech, Inc. | 1 | -88% |
| Genzyme Corporation | 0 | -100% |
| F. Hoffmann-La Roche AG | 0 | -100% |
| Wyeth LLC | 0 | — |
| Ares Trading S.A. | 0 | -100% |
| Life Technologies Corporation | 0 | -100% |
| Repligen Corporation | 0 | -100% |
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Perfusion and Process Intensification covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's Next
Where to take this next
The landscape points to a field with a settled core and some lighter-claimed edges. Two directions are worth pursuing depending on what you're trying to decide.
Check freedom-to-operate against the leader's portfolio
With one assignee holding 772 records against a fifth-place figure of 174, any new perfusion or cell retention filing should be checked against that single portfolio first, not just the aggregate top ten.
Run a freedom-to-operate scan in EurekaDraft around the lighter apparatus classes
B01D and C12M coverage sits well below the dominant biological classes, suggesting more room for apparatus-specific claims around filtration and retention hardware than around the underlying cell biology.
Explore white space in EurekaSource: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Perfusion and Process Intensification covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ
Common questions about this landscape
One assignee leads the ranked field with 772 records, well ahead of the fifth-place holder at 174 and the tenth-place holder at 90. The top five assignees combined account for 35.7% of all 4,506 records in scope, and the top ten reach 47.4%. This concentration means a small group of established biologics manufacturers controls most of the core claim space around cell retention and perfusion control methods.
Filings rose from 205 in 2017 to a peak of 322 in 2021, then fell to 215 by 2024 — a 33% decline over that three-year span, which is the last period the dataset treats as complete. Numbers for 2025 and 2026 look lower still, but that reflects the roughly 18-month lag between filing and publication rather than a genuine collapse in activity. The honest read is a pullback from a 2021 peak, not a dying field.
C12N (microorganisms and genetic engineering) appears in 57.6% of the 4,506 records, and C07K (peptides and proteins) in 37.6%, making this a biology-first field rather than an apparatus-first one. C12M, the class covering bioreactors and enzyme apparatus, sits at 25.1% — present but secondary. Filtration-specific claims under B01D cover just 10.3% of records, which is comparatively light given how central cell retention and filter fouling are to the field's search terms.
The lighter-claimed branches sit in apparatus and monitoring rather than core biology: filtration and separation processes (B01D) cover only 10.3% of records, and material analysis and testing (G01N) just 3.4%. Specific sub-areas worth examining include filter fouling detection sensors, perfusion rate control algorithms and steady-state operation monitoring, all of which sit adjacent to the dominant C12N and C07K claims without being crowded by them. A first claim in these areas would need to tie a specific sensing or control mechanism to a named operational parameter rather than claiming the biological process broadly.
SG11201809051YA, filed by Boehringer Ingelheim International GmbH and titled 'Cell retention device and method', is a representative filing in the cell retention device sub-area of this dataset. It combines an apparatus claim with a method claim, which is a common structure across this field's retention-device filings. Anyone designing a new retention system for perfusion culture should review this filing's specific claim scope before finalising a device architecture, since apparatus-plus-method claims of this type tend to have broader effective coverage than a device claim alone.
Answers are grounded in the same dataset. Derived from a Patsnap search on Perfusion and Process Intensification covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Research Perfusion and Process Intensification in depth with Eureka
Go past this page: query the whole perfusion and process intensification corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.